Clinical trials: Mood Change
Major Depressive Disorder, Soft Tissue Discomfort Syndrome
Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome
The objective of this study is to determine the time course of duloxetine efficacy on the symptoms of Major Depressive Disorder (MDD)and on the symptoms of Soft Tissue Discomfort Syndrome(STDS) via use of 24-hour Actigraph™…
- Conditions
- Major Depressive Disorder, Soft Tissue Discomfort Syndrome, Pain
- Trial name
- NCT01035073
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Pennsylvania
Major Depressive Disorder, Cognitive Change
THINC-it Vortioxetine - Sensitivity to Change
The purpose of this study is to evaluate the sensitivity of the THINC-it tool, in measuring change in cognitive deficits in individuals with MDD after receiving vortioxetine.
- Trial name
- NCT03053362
- Testing
- Vortioxetine, THINC-it Tool
- Where
- Canada
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Brain and Cognition Discovery Foundation
Major Depressive Disorder
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder
The purpose of this study is to explore patterns of Brain Network Activation (BNA) changes from baseline to endpoint on 1) efficacy of core symptoms of Major Depressive Disorder (MDD) and 2) improvement of cognitive dysfunction…
- Trial name
- NCT02749721
- Testing
- vortioxetine
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Rush University Medical Center
Depression, Obesity
Research Aimed at Improving Both Mood and Weight
The RAINBOW study is an NIH R01-funded randomized controlled trial to evaluate the clinical and cost effectiveness and implementation potential of a primary care integrated multicondition intervention program to help improve mood…
- Trial name
- RAINBOW-ENGAGE (NCT02246413)
- Testing
- RAINBOW Intervention Program
- Where
- 2 sites in United States
- Volunteers
- 409 people
- Sponsor
- Palo Alto Medical Foundation
Major Depressive Disorder
Supportive and Supportive-Expressive Treatment for Depression
This study will assign patients to two types of psychotherapies in treating people with a major depression disorder, expressive versus supportive techniques, and will examine their ability to benefit from treatment based on their…
- Trial name
- SSETD (NCT02728557)
- Testing
- Supportive-Expressive Therapy, Supportive Therapy
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- University of Haifa
Bipolar Disorder
N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder
We propose to conduct a double-blind placebo-controlled trial with a widely available and prototypical non-steroidal anti-inflammatory agent, aspirin, and an antioxidant agent, NAC, involving symptomatic Bipolar Disorder type I…
- Trial name
- SMRI-Bipolar (NCT01797575)
- Testing
- Aspirin, N-acetyl-cysteine (NAC), Sugar Pill
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- The University of Texas Health Science Center, Houston
Nutrient Deficiency, Happiness
Alii Supplement Study
The goal of this clinical trial is to learn if the Alii Supplement can be used to reduce symptoms related to nutritional depletion in hormonal birth control pill users.
- Conditions
- Nutrient Deficiency, Happiness, Digestive Health, Vulnerability to Disease
- Trial name
- NCT07271316
- Testing
- Alii Supplement
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Texas Christian University
Depression, Bipolar Disorder
Augmenting Hospitalization for Serious Mental Illness: Cognitive Bias Modification
Approximately 4.1% of the adult US population meets the criteria for SMI, a mental disorder associated with significant functional impairment.
- Conditions
- Depression, Bipolar Disorder, Anxiety Disorders, Psychiatric Disorder
- Trial name
- NCT03509181
- Testing
- I-Change, Symptom Tracking
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Mclean Hospital
Depression
Behavioral Study of Effects of Low-Level Light Therapy on Mood and Reaction Time
The goal of this project is to use low-level light therapy (LLLT) to enhance neural metabolism in the prefrontal cortex of humans, and measure the effects of LLLT on attentional bias change following a single session of attention…
- Trial name
- NCT02390076
- Testing
- Left Low Level Light Therapy, Attention bias modification, Right Low Level Light Therapy
- Volunteers
- 51 people
- Sponsor
- Seth Disner
Schizophrenia, Bipolar 1 Disorder
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls.
- Conditions
- Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
- Trial name
- NCT03643159
- Testing
- Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression
Investigating whether delta-beta cross-frequency transcranial alternating current stimulation can augment the effects of a single session of behavioral activation in participants with major depressive disorder.
- Trial name
- ABBA (NCT05693922)
- Testing
- Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC, Single-session behavioral activation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizoaffective Disorder
Naltrexone for Antipsychotic-Induced Weight Gain
This study is designed to look at the effects of naltrexone on weight loss in individuals treated with antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder
- Trial name
- NTX (NCT01866098)
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Yale University
Bipolar Disorder
Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder
This study evaluated whether lithium included as part of optimized medication treatment improved overall level of illness, symptoms of mania and depression, and quality of life in people with bipolar disorder.
- Trial name
- LiTMUS (NCT00667745)
- Testing
- Lithium Carbonate, Optimized Treatment (OPT)
- Where
- 6 sites in United States
- Volunteers
- 283 people
- Sponsor
- National Institute of Mental Health (NIMH)
Metabolic Complications
Metformin for the Prevention of the Metabolic Side-effects of Zyprexa
We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo.
- Trial name
- NCT00682448
- Testing
- Metformin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Rush University Medical Center
Treatment Resistant Depression
Establishing a Dose-response Relationship With Accelerated Transcranial Magnetic Stimulation
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- NCT04243798
- Testing
- Active TBS-DLPFC
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Stanford University
Major Depressive Disorder
A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.
The purpose of this study is to measure if there is any difference in how the body breaks down or inactivates either fluoxetine or LY2216684 when both of these medicines are given together.
- Trial name
- NCT01243957
- Testing
- LY2216684, Fluoxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Bipolar Disorder, Medication Adherence
CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)
This is a prospective study using customized adherence enhancement (CAE) and long-acting injectable (LAI) antipsychotic in 30 individuals with bipolar disorder (BD) at risk for treatment non-adherence.
- Conditions
- Bipolar Disorder, Medication Adherence, Medication Non Adherence
- Trial name
- NCT03408873
- Testing
- Abilify Maintena, Customized Adherence Enhancement (CAE)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Martha Sajatovic
Major Depression
Motivational Interviews for Depression in Primary Care
The purpose of the study is to determine whether motivational interviewing with guideline-based medical management for depression will significantly improve time to depression recovery and increase the proportion of subjects in…
- Trial name
- NCT01114334
- Testing
- Guideline-Based Medical Management, Motivational Interviewing for Depression
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Denver Health and Hospital Authority
Major Depressive Disorder
Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness of treatment with vortioxetine on participant goal achievement after a change in antidepressant medication for the treatment of major depressive disorder (MDD).
- Trial name
- NCT02972632
- Testing
- Vortioxetine
- Where
- 25 sites in United States
- Volunteers
- 123 people
- Sponsor
- Takeda
Asthma, Rheumatic Disease
Acetaminophen (Tylenol) for Mood and Memory Changes Associated With Corticosteroid Therapy
Studies in humans and animals support that stress and/or elevations in corticosteroids lead to changes in hippocampal structure and functioning.
- Trial name
- NCT00377364
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center